Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03598816
Title PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine

renal cell carcinoma


Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries

No variant requirements are available.